

Yıldız ATAMER¹
Yüksel KOÇYİĞİT²
Aytaç ATAMER³
Nuriye METE¹
Naime CANORUÇ¹
Gülten TOPRAK¹

Alterations of Erythrocyte and Plasma Lipid Peroxides as well as Antioxidant Mechanism in Patients with Type II Diabetes Mellitus (NIDDM)

Received: May 28, 1996

Abstract: It has been maintained that free oxygen radicals (FOR) that occur in cell have important roles in the etiopathogenesis of diabetes, and that cell damage progressing as a result of their accumulation is responsible for the development of diabetic complications. In recent years, along with free oxygen radicals, antioxidant mechanisms and the substances influencing as free radical cleaner have been investigated in connection with diabetes. With this respect, in a total of 30 patients with type II Diabetes Mellitus (NIDDM), 15 with diabetic retinopathy and 15 without diabetic retinopathy, and in 20 healthy subjects, we measured glutathione (GSH), catalase and antiperoxidant superoxide dismutase (SOD) levels as well as plasma and erythrocyte levels of Malondialdehyde (MDA), which is the last product of oxidation of polyunsaturated fatty acids.

abiotic groups, erythrocyte and plasma levels were observed to have increased considerably when compared with those in the control group ($P < 0.001$). It was determined that, while erythrocyte SOD, catalase and glutathione levels in the groups with diabetic retinopathy decreased significantly relative to those in the control group, a slight decrease occurred in the SOD levels of the group without diabetic retinopathy with respect to controls, and that this, however, was statistically insignificant ($P < 0.05$). Still, the decrease in the catalase and glutathione levels was found to be significant ($P < 0.02$).

These results indicate that accompaniment of inhibited antioxidant defence systems with increased lipid peroxide levels leading to damage in endothelial cell membrane is important not only in the progress of diabetes but also in the development of diabetic complications.

Key Words: Lipid peroxidation, Superoxide dismutase, catalase, glutathione.

Departments of ¹Biochemistry, ²Physiology, ³Internal Disease, Faculty of Medicine, Dicle University, Diyarbakır-Turkey

Erythrocyte and plasma MDA levels of patients with diabetic retinopathy were higher relative to those without diabetic retinopathy ($P < 0.001$, $P < 0.005$). In both di-

Introduction

It is maintained that erythrocyte lipid peroxide levels are increased in diabetes and that high plasma lipid peroxides (LPO) in diabetes may result from oxidative destruction of erythrocyte membrane lipids (1). Erythrocytes are unique biological entities that contain molecular oxygen, ferrous ions and polyunsaturated fatty acids at high concentrations.

In erythrocytes, auto-oxidation of oxyhemoglobin into methemoglobin, interaction of hemoglobin with redox drugs and xenobiotics, Fenton and Haber-Weiss reactions catalyzed with metal (Fe) are factors that may lead to free radical production (2). Bond-dissociation energies of allylic hydrogens found in the structure of phospholipids in erythrocyte membranes are quite low. Therefore, polyunsaturated fatty acids are more sensitive to oxidative damage, but erythrocytes are resistant to oxidative damage. Because, in

their structure, there are enzymes and molecules such as catalase, SOD, glutathione peroxidase (GSH-Px) and glutathione, which are found in antioxidant mechanism (2,3). Of these, catalase catalyses the destruction of H_2O_2 and other hydrogen donors. This enzyme found at the highest concentration in human liver and kidney is at lower levels in serum. Other antioxidant enzyme SOD is an enzyme that eliminates superoxide radicals effectively, being identical with erythrocyte protein (4). GSH redox cycle, one of antioxidant systems, constitutes the main system to reduce hydroperoxides that are formed in the cell. Key enzyme of cycle is glutathione peroxidase, substrate of which is reduced glutathione (GSH) (5).

LPO products are damaging endothelial and intima cells, increasing thrombocyte aggregation and inhibiting prostacyclin synthesis. By increasing the consumption of antioxidant substances such as SOD,




Figure 1. Showing of the alterations in MDA levels in diabetics with retinopathy and without retinopathy relative to those of the control group.

catalase, glutathione peroxidase, glutathione and vitamin E, superoxide radicals (SOR) and lipid peroxidation products make the defense systems within the cell insufficient and can also inhibit the activity of SOD (6).

Starting out from these preliminary data, are investigated the levels of plasma and erythrocyte MDA, alterations in the levels of erythrocyte SOD, catalase and glutathione, and thereby the effects of these alterations upon the complications developing in diabetes.

Materials and Methods

In this study, 30 patients hospitalized in Diy-erbakyr SSK Hospital with diagnosis of type II Diabetes mellitus, 15 patients of whom developed retinopathy and the other 15 patients did not develop retinopathy, and 20 healthy subjects (10 male, 10 female) whose ages were varying between 43-53, and who did not use any drugs, alcohol and cigarettes, without any history of disease were included in the study. Of diabetics that were composed of 18 female and 12 male, retinopathy group had age varying between 44-58 and diabetic duration was 5-15 years, while the group without retinopathy had age varying between 42-55, and diabetic duration was 3-12 years. Variations in diabetes duration and ages are presented in Table 1. Most of the patients were administered oral antidiabetic or insulin under medical treatment. Heparinized blood samples were taken from each pa-

tient fasting overnight (before insulin administration in those using insulin).

The erythrocytes package was prepared by washing the erythrocytes fractioned blood plasma taken by heparin with 0.15 mol/L NaCl solution at a rate of 1:5 three times, and by centrifuge them at 3000 rpm for ten minutes each time. The measurements of SOD, catalase, GSH and erythrocyte MDA were conducted in erythrocyte; those of plasma MDA level were carried out in plasma.

Erythrocyte LPO was measured by Stocks and Dormandy's thiobarbituric acid (TBA) method (7); plasma LPO by TBA method modified from Takeuchi (8). Erythrocyte GSH was measured by 2-nitrobenzoic acid (DTNB) method from Beutler (9); Erythrocyte SOD was measured by modified Winterbourn and Hawkins' method based upon reduction of nitroblue tetrasolium (NBT) (10).

Catalase levels were determined by Aebi's modified colorimetric method (11). It is based upon alteration of H_2O_2 optic density, depending upon enzymatic decomposition of H_2O_2 (by the effect of catalase in the sample). Data were changed to k/g Hb after "k" value was determined, taking suitable absorbans for each analysis according to calculated regression. Drabkin's method was used to determine erythrocyte hemoglobin.

In the statistical evaluation of the results, the difference between averages of the two experiments series was determined by "student's t" test.




Figure 2. Showing of the alterations in erythrocyte SOD activities in diabetics with retinopathy and without retinopathy relative to those of the control group




Figure 3. Showing of the alterations in erythrocyte catalase activities in diabetics with retinopathy and without retinopathy relative to those of the control group

Results

The results obtained from control and both diabetic groups are shown statistically in Table 1-4 According to these;

(a) The difference between the age averages of control and diabetics, and those of diabetics with and without retinopathy as well as the difference between diabetic duration were not found statistically significant ($P > 0.05$) (Table 1).

(b) SOD, catalase, glutathione levels of diabetics are significantly lower ($P < 0.001$), while glucose, eryth-

rocytes and plasme MDA levels were significantly higher, when compared with those of control group ($P < 0.001$) (Table 2).

(c) Glucose, erythrocyte and plasma MDA levels of the group with retinopathy were significantly higher ($P < 0.001$, $P < 0.005$), whereas SOD, catalase and glutathione levels were significantly lower relative to those of the group without retinopathy ($P < 0.001$) (Table 3).

(d) Erythrocyte MDA and plasma MDA levels of the group without retinopathy were significantly high-




Figure 4. Showing of the alterations in erythrocyte glutathione activities in diabetics with retinopathy and without retinopathy relative to those of the control group

er ($P < 0.001$) (Figure 1), catalase and glutathione levels were lower ($P < 0.02$) when compared to control group (Figure 3, 4). Although SOD levels were lower relative to those of control group, the difference was not found statistically significant $P > 0.05$ (Table 4) (Figure 2).

(e) Glucose, erythrocyte and MDA levels of the group with retinopathy were significantly higher ($P < 0.001$) (Figure 1); SOD, catalase and GSH levels were significantly lower, when compared to control group ($P < 0.001$) (Table 4) (Figure 2, 3, 4).

Discussion

Alterations in increased lipid peroxidation free radicals and antioxidant defense systems have been investigated as related with diabetes in recent years. It was demonstrated that free fatty acids increasing in the lack of insulin contributed to increased plasma LPO levels. Insulin reduces hepatocyte LPO production. In addition, since insulin activates glutathione peroxidase that breaks LPO, hepatocytes can not remove LPO in the lack of insulin (12).

By most researchers, it was demonstrated that lipid peroxides (MDA) were higher in diabetics with retinopathy relative to diabetics without retinopathy (1,13-16). We also identified higher plasma and erythrocyte LPO (MDA) levels in the group with retinopathy, compared with those in the group without retinopathy. There are a few biochemical mechanism that explain the reason for this rise. The increasing of blood free fatty acid levels depending on lypolys increase results in increase in MDA production. In the

excessive production of free radicals, it leads to microvascular lesions. These lesions are associated with dysfunction of biologic antioxidant systems (17, 18, 19). It has been seen that this damage is more severe in ketotic period. This was attributed to the decreasing of cytoplasmic NADPH due to blockage of pentose phosphate shunt and dysfunction of glutathione of synthetase (18).

Increased LPO levels of diabetic individuals may take origin from peroxidative damage of membrane lipids. Jennings et al. (13) have shown that increased free radical activity leads to an increased thrombotic tendency and a reduction in prostacyclin stimulating factor, depending on increasing thrombocyte reactivity in diabetics (especially with retinopathy), and they have also demonstrated that intracellular SOD activity is reduced in patients with retinopathy (13). Most researchers actually have shown that prostanoids and lipid peroxides accepted as an index of intravascular free radicals are effective in the beginning and development of microangiopathy and that valuable results can be achieved in the prevention of diabetic microangiopathy progress through lipid control along with glysemic control (13,15,16,20,21).

In a number of studies, it was established that abnormalities in blood parameters of patient with diabetic complication and non-regulated well (Retinopathy, neuropathy, nephropathy, peripheral vascular disorders, coronary or cerebral diseases and the like) were much more when compared with those patients well regulated and without complication. (20, 22) Since lipid peroxides play a major role in the formation of vascular tissue damage, it is suggested that LPO,

increasing in diabetes can be effective in the pathogenesis of diabetic angiopathy. (20,22) It has been indicated that free fatty acids increasing in the lack of insulin contribute to high plasma LPO levels. (22)

One of the intracellular protective mechanisms against free radicals that form peroxidation in membrane lipids is glutathione and redox system. Reduced GSH is a non-specific reduction agent and plays an important role in oxidation mechanisms. In cell metabolism, it performs important functions in the prevention of sulphhydryl groups of various proteins and lipoproteins in cell membrane. GSH participates in antioxidative defense system as free radical inactivator (19). It is accepted that, as thrombocyte GSH level is decreased in diabetes, increased thromboxan A₂ (TXA₂) synthesis prepares ground for vascular complications by increasing thrombocyte activity. In the existence of GSH, which is a cofactor of GSH-Px (Glutathione peroxidase) enzyme it inhibits sikkooxygenesis by removing LPO from the medium. However, LPO accumulated in the cell stimulates TXA₂ synthesis, in the lack of GSH, or when GSH-Px activity is decreased (23). Some researchers recognized that SOD and catalase levels in well-regulated diabetics did not exhibit difference with respect to control group (21,24).

It has been suggested that excessive free radical production causes microvascular lesions, and that they are related with dysfunction of biological antioxidant systems of these lesions (18). In the lack of SOD, hydroxyl radical singlet oxygen produced through fenton reaction and dismutation of superoxide by its own accord initiate lipid peroxidation in especially unsaturated fatty acids. These two radicals are the most toxic and effective radicals that lead to lipid peroxidation. There-

fore, it is accepted that these two radicals are essentially responsible for changes in the membranes of tumour cells (25,26).

Hayakawa et al (20), have reported that increased lipid peroxide causes damage in endothelial cell membranes, that inhibition of antioxidants marks this damage and that this status is important in the pathogenesis of diabetic complications (20).

As a result, we are of the opinion that;

1. Increase in lipid peroxides accepted as an index for intravascular free radicals is effective in the initiation and evolution of microangiopathy in diabetics,

2. An inefficiency occurs in antioxidant defense systems, depending upon lipid peroxidation increase or inhibition of antioxidant defense systems.

Most investigators have observed that erythrocyte glutathione levels are decreased in diabetic individuals (1,5,18,23). We have also observed that GSH activity has decreased in both diabetic groups. However the decrease in GSH levels was clearer in the group with retinopathy.

It has demonstrated by most researchers that SOD and catalase activities were reduced in non-regulated diabetics, but unchanged in well-regulated diabetics (17,18,20,21).

In our study, while SOD and catalase levels were significantly decreased in the group with retinopathy, the decrease determined in SOD levels of the group without retinopathy was found to be insignificant. However, the decrease identified in catalase levels of the group without retinopathy was found significant.

References

1. Uzel N, Sivas A, Uysal M, Öz H. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with diabetes mellitus. *Horm Metabol Res* 9:89-90, 1987.
2. Freeman BA, Crapo JD. Biology of disease. Free radicals and tissue injury. *Lab Invest* 47: 412-426, 1982.
3. Gutteridge JMC, Halliwell B. The measurement and mechanism of lipid peroxidation in biological systems. *Trends Biochem Sci* 15: 129-135, 1990.
4. Sözmen EY, Onat T, Tanyalçın T, Erilaçın S. Age correlated modifications of antioxidant enzyme activities in human erythrocytes. *Journal of Biochemistry XVIII*, 3, 83-89, 1993.
5. Costagliola C. Oxidative state of glutathione in red blood cells and plasma of diabetic patients *Clin Physiol Biochem* 8: 204, 1990.
6. Loeper I, Goy J, Rozenstain L, Bedu O, Moisson. Lipid peroxidation and protective enzymes during myocardial infarction. *Clin Chim Acta* 196: 119, 1991.
7. Stocks J and Dormandy TL. The autoxidation of human red cell lipids induced by hydrogen peroxide. *Brit J Hematol* 20: 95-111, 1971.
8. Takeuchi N, Tanaka F, Katayama Y, Matsumiya K and Yamamura Y. Effects of a-tocopherol on thiobarbituric acid reactive substances in serum and hepatic subcellular organelles and lipid metabolism. *Exp Gerontol* 11: 179-185, 1976.
9. Beutler E, Duran O and Kelly BM. Improved method for the determination of blood glutathione. *J Lab Clin Med* 61 (5): 882-888, 1963.

10. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. *J Lab Clin Med* 85 (2): 337, 1975.
11. Aebi H. Catalase in vitro. *Methods in enzymology* 105:121, 1984.
12. Kosugi K, Harano Y, Kashiwagi A, Suzuki M. Effect of insulin synthesis and release of lipid peroxide by cultured hepatocytes isolated from normal and diabetic rats. *Experientia* 40: 394-6, 1984.
13. Jennings PE, McLaren M, Scott NA, Saniabadi AR, Belch JJ. The relationship of oxidative stress to thrombotic tendency in type 1 diabetic patients with retinopathy. *Diabet Med* 8(9): 860-5, 1991.
14. Gallau G, Ruelland A, Legras B, Maugendre D, Allanninc H, Cloarec L. Plasma malondial-dehyde in type 1 and type 2 diabetic patients. *Clin Chim Acta* 214 (2): 227-34, 1993.
15. Augustin AJ, Breipohy W, Boker T, Llutz J, Spitznas M. Increased lipid peroxide levels and myeloperoxidase activity in the vitreous of patients suffering from proliferative diabetic retinopathy. *Graefes Arch Clin Exp Ophthalmol* 231 (11): 647-50, 1993.
16. Katoh K. Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic type 2 diabetes mellitus *Diabetes. Res Clin Pract* 18 (2): 89-98, 1992.
17. Cousins RJ: Absorption, transport and hepatic metabolism of copper and zinc: Special reference to MTN and CP. *Am Physiol Soc*, 238-309, 1985.
18. Faure P, Corticelli P, Richard MJ, Arnaud J, Coudray C, Halimi S, Favier A and Roussel AM. Lipid peroxidation and trace element status in diabetic ketotic patients: Influence of Insulin therapy. *Clin Chem* 39/5, 789-793, 1993.
19. Kynlaw WB: Abnormal zinc metabolism in diabetes mellitus. *Am J Med*, 75: 273-277, 1983.
20. Hayakawa M, Kuzuya F. Free radicals and diabetes mellitus. *Nippon Ronen Igakkai Zasshi* 27 (2): 149-54, 1990.
21. Balashova TS, Golega EN, Rud'ko IA, Balabolkin MI, Kubatieve AA. Lipid peroxidation and the antioxidant protection of the erythrocytes in diabetes mellitus patients. *Tre Arkh* 65 (10): 23-7, 1993.
22. Kosugi K, Harano Y, Kashiwagi A, Suzuki M: Effect of insulin synthesis and release of lipid peroxide by cultured hepatocytes isolated from normal and diabetic rats. *Experientia*, 40: 394-6, 1984.
23. Dingiloğlu N, Özmen D, Bayındır O, Kutay F, Yılmaz C. Erythrocyte and plasma lipid peroxides, erythrocyte GSH and glucose-6-P dehydrogenase levels in diabetics. *Journal of Biochemistry XVIII: (3)*, 13-18, 1993.
24. Volkovova K, Chorvathova V, Jurcovicova M, Koszeghyova L, Bobek P. Antioxidative state of the myocardium and kidneys in acute diabetic rats. *Physio Res* 42 (4): 251-5, 1993.
25. Kılınç K. Oxygen radicals and superoxide dismutase in cancer. *Biochemistry XI (3)*, 59-76, 1986.
26. Collier A, Wilson R, Bradley H, Thomson JA, Small M. Free radical activity in type 2 diabetes. *Diabet Med* 7(1): 27-30, 1990.